Findings

What do systematic reviews say?

2 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

GnRH agonist plus chemotherapy vs chemotherapy alone

Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy

GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).

2 findings from 1 review

Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
RR 1.6 [1.14, 2.24]
5 studies · 460 participants
Low
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
RR 1.08 [0.95, 1.22]
8 studies · 869 participants
Low

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy

It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).

2 findings from 1 review

Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
RR 1 [0.76, 1.32]
1 study · 50 participants
Very low
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
RR 0.93 [0.56, 1.55]
1 study · 50 participants
Very low